The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age

References

• Lyall F, Greer I A, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997; 104: 223–228
   PubMedGoogle Scholar
• Kupferminc M J, Daniel Y, Englender T, Baram A, Many A, Jaffa A J, Gull I, Lessing J B. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 1997; 38: 302–306
   PubMed Web of Science ®Google Scholar
• Torry D S, Wang H S, Wang T H, Caudle M R, Torry R J. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539–1544
   PubMed Web of Science ®Google Scholar
• Tidwell S C, Ho H N, Chiu W H, Torry R J, Torry D S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267–1272
   PubMed Web of Science ®Google Scholar
• Tjoa M L, van Vugt J M, Mulders M A, Schutgens R B, Oudejans C B, van Wijk I J. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98: 600–607
   PubMed Web of Science ®Google Scholar
• Chappell L C, Seed P T, Briley A, Kelly F J, Hunt B J, Charnock-Jones D S, Mallet A I, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187: 127–136
   PubMed Web of Science ®Google Scholar
• Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher S J. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405–1423
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR–1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–2351
   PubMed Web of Science ®Google Scholar
• Maynard S E, Min J Y, Merchan J, Lim K H, Li J, Mondal S, Libermann T A, Morgan J P, Sellke F W, Stillman I E, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658
   PubMed Web of Science ®Google Scholar
• Taylor R N, Grimwood J, Taylor R S, McMaster M T, Fisher S J, North R A. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177–182
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, Brichant J F, Pignon M R, Noel A, Schaaps J P, Cabrol D, Frankenne F, Foidart J M. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555–5563
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee K Y, Goncalves L F, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541–1547
   PubMed Web of Science ®Google Scholar
• Krauss T, Pauer H U, Augustin H G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101–111
   PubMed Web of Science ®Google Scholar
• Levine R J, Maynard S E, Qian C, Lim K H, England L J, Yu K F, Schisterman E F, Thadhani R, Sachs B P, Epstein F H, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683
   PubMed Web of Science ®Google Scholar
• McKeeman G C, Ardill J E, Caldwell C M, Hunter A J, McClure N. Soluble vascular endothelial growth factor receptor–1 (sFlt–1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240–1246
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter W P, Wolf M, Levine R J, Taylor R N, Sukhatme V P, Ecker J, Karumanchi S A. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770–775
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim Y M, Kim G J, Kim M R, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, et al. Plasma soluble vascular endothelial growth factor receptor–1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers R W, Larkin R W, Gilmour C, Bodnar L M, Crombleholme W R, Ness R B, Roberts J M, Hubel C A. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895–4903
   PubMed Web of Science ®Google Scholar
• Staff A C, Braekke K, Harsem N K, Lyberg T, Holthe M R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122: 33–39
   PubMed Web of Science ®Google Scholar
• Levine R J, Thadhani R, Qian C, Lam C, Lim K H, Yu K F, Blink A L, Sachs B P, Epstein F H, Sibai B M, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293: 77–85
   PubMed Web of Science ®Google Scholar
• Levine R J, Lam C, Qian C, Yu K F, Maynard S E, Sachs B P, Sibai B M, Epstein F H, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992–1005
   PubMed Web of Science ®Google Scholar
• Robinson C J, Johnson D D, Chang E Y, Armstrong D M, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195: 255–259
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y M, Bdolah Y, Lim K H, Yuan H T, Libermann T A, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–649
   PubMed Web of Science ®Google Scholar
• Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201–207
   PubMed Web of Science ®Google Scholar
• Boutsikou T, Malamitsi-Puchner A, Economou E, Boutsikou M, Puchner K P, Hassiakos D. Soluble vascular endothelial growth factor receptor–1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 2006; 82: 235–239
   PubMed Web of Science ®Google Scholar
• Girardi G, Yarilin D, Thurman J M, Holers V M, Salmon J E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203: 2165–2175
   PubMed Web of Science ®Google Scholar
• Savvidou M D, Yu C K, Harland L C, Hingorani A D, Nicolaides K H. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol 2006; 195: 1668–1673
   PubMed Web of Science ®Google Scholar
• Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien J, Edwin S, Kim Y, Hong J, Goncalves L, et al. Preeclampsia and SGA differ in the maternal plasma complement split products profile. J Soc Gynecol Investig 2005; 12, 148a Abstract
   Google Scholar
• Wallner W, Sengenberger R, Strick R, Strissel P L, Meurer B, Beckmann M W, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112: 51–57
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien J K, Goncalves L, Edwin S, Kim Y M, Erez O, Kusanovic J P, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestation age. J Matern Fetal Neonatal Med 2008; 21(1)41–52
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Espinoza J, Gotsch F, Kim Y M, Kim G J, Goncalves L F, Edwin S, Kusanovic J P, Erez O, Than N G, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008; 21(1)25–40
   PubMed Web of Science ®Google Scholar
• Di Renzo G C. The of the ‘anti-angiogenic state’ in complications of pregnancy. J Matern Fetal Neonatal Med 2008; 21(1)3–7
   PubMed Web of Science ®Google Scholar
• Audibert F, Benchimol Y, Benattar C, Champagne C, Frydman R. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Fetal Diagn Ther 2005; 20: 48–53
   PubMed Web of Science ®Google Scholar
• Muller P R, James A H, Murtha A P, Yonish B, Jamison M G, Dekker G. Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester. Hypertens Pregnancy 2006; 25: 183–192
   PubMed Web of Science ®Google Scholar
• Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818–824
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Nien J K, Gomez R, Kusanovic J P, Goncalves L F, Medina L, Edwin S, Hassan S, Carstens M, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196: 326.e1–13
   PubMed Web of Science ®Google Scholar
• Vatten L J, Eskild A, Nilsen T I, Jeansson S, Jenum P A, Staff A C. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196: 239–246
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi S A, Levine R J, Venkatesha S, Rauh-Hain J A, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137–142
   PubMed Web of Science ®Google Scholar
• Clark D E, Smith S K, He Y, Day K A, Licence D R, Corps A N, Lammoglia R, Charnock-Jones D S. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540–1548
   PubMed Web of Science ®Google Scholar
• Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145: 4838–4845
   PubMed Web of Science ®Google Scholar
• Shore V H, Wang T H, Wang C L, Torry R J, Caudle M R, Torry D S. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18: 657–665
   PubMed Web of Science ®Google Scholar
• St Jacques S, Forte M, Lye S J, Letarte M. Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 1994; 51: 405–413
   PubMed Web of Science ®Google Scholar
• Khaliq A, Li X F, Shams M, Sisi P, Acevedo C A, Whittle M J, Weich H, Ahmed A. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors 1996; 13: 243–50, color
   PubMed Web of Science ®Google Scholar
• Dagdeviren A, Muftuoglu S F, Cakar A N, Ors U. Endoglin (CD 105) expression in human lymphoid organs and placenta. Ann Anat 1998; 180: 461–469
   PubMed Web of Science ®Google Scholar
• Gonzalez R P, Gomez R M, Castro R S, Nien J K, Merino P O, Etchegaray A B, Carstens M R, Medina L H, Viviani P G, Rojas I T. [A national birth weight distribution curve according to gestational age in chile from 1993 to 2000]. Rev Med Chil 2004; 132: 1155–1165
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–S22
   PubMed Web of Science ®Google Scholar
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159–167
   PubMed Web of Science ®Google Scholar
• Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA 1991; 266: 237–241
   PubMed Web of Science ®Google Scholar
• Bobrowski R A, Bottoms S F. Underappreciated risks of the elderly multipara. Am J Obstet Gynecol 1995; 172: 1764–1767
   PubMed Web of Science ®Google Scholar
• Sibai B M, Gordon T, Thom E, Caritis S N, Klebanoff M, McNellis D, Paul R H. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1995; 172: 642–648
   PubMed Web of Science ®Google Scholar
• Caritis S, Sibai B, Hauth J, Lindheimer M, VanDorsten P, Klebanoff M, Thom E, Landon M, Paul R, Miodovnik M, et al. Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1998; 179: 946–951
   PubMed Web of Science ®Google Scholar
• Odegard R A, Vatten L J, Nilsen S T, Salvesen K A, Austgulen R. Risk factors and clinical manifestations of pre-eclampsia. BJOG 2000; 107: 1410–1416
   PubMed Web of Science ®Google Scholar
• O'Brien T E, Ray J G, Chan W S. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003; 14: 368–374
   PubMed Web of Science ®Google Scholar
• Bodnar L M, Ness R B, Markovic N, Roberts J M. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol 2005; 15: 475–482
   PubMed Web of Science ®Google Scholar
• Doherty D A, Magann E F, Francis J, Morrison J C, Newnham J P. Pre-pregnancy body mass index and pregnancy outcomes. Int J Gynaecol Obstet 2006; 95: 242–247
   PubMed Web of Science ®Google Scholar
• Bodnar L M, Catov J M, Klebanoff M A, Ness R B, Roberts J M. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology 2007; 18: 234–239
   PubMed Web of Science ®Google Scholar
• Romero R, Nien J K, Espinoza J, Todem D, Fu W, Chung H, Kusanovic J P, Gotsch F, Erez O, Mazaki-Tovi S, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble VEFG Receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and small for gestational age neonates. Journal of Maternal-Fetal and Neonatal Medicine 2008; 21(1)9–23
   PubMed Web of Science ®Google Scholar